BioAtla (BCAB) News Today → Who are Nvidia’s New Silent Partners? (From Weiss Ratings) (Ad) Free BCAB Stock Alerts $1.51 0.00 (0.00%) (As of 05/31/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 29, 2024 | globenewswire.comBioAtla to Participate in the Jefferies Global Healthcare ConferenceMay 24, 2024 | americanbankingnews.comBioAtla (NASDAQ:BCAB) PT Lowered to $5.00 at JMP SecuritiesMay 23, 2024 | globenewswire.comBioAtla Presenting Phase 1 Evalstotug Clinical Trial Data Demonstrating Clinical Benefit at the Upcoming 2024 American Society of Clinical Oncology (ASCO) Annual MeetingMay 23, 2024 | markets.businessinsider.comBuy Rating for BioAtla: Promising Clinical Data and Strong Financial Position Signal Upside PotentialMay 23, 2024 | marketbeat.comBioAtla (NASDAQ:BCAB) Price Target Lowered to $5.00 at JMP SecuritiesJMP Securities cut their target price on shares of BioAtla from $12.00 to $5.00 and set a "market outperform" rating on the stock in a research report on Thursday.May 23, 2024 | finance.yahoo.comInstitutional owners may consider drastic measures as BioAtla, Inc.'s (NASDAQ:BCAB) recent US$35m drop adds to long-term lossesMay 17, 2024 | marketbeat.comHC Wainwright Analysts Increase Earnings Estimates for BioAtla, Inc. (NASDAQ:BCAB)BioAtla, Inc. (NASDAQ:BCAB - Free Report) - HC Wainwright boosted their Q2 2024 earnings per share (EPS) estimates for BioAtla in a note issued to investors on Wednesday, May 15th. HC Wainwright analyst A. He now forecasts that the company will post earnings of ($0.51) per share for the quarter,May 15, 2024 | markets.businessinsider.comBuy Rating Affirmed for BioAtla on Strong Clinical Data and Strategic Pipeline ProgressMay 15, 2024 | marketbeat.comBioAtla (NASDAQ:BCAB) Earns Buy Rating from HC WainwrightHC Wainwright reiterated a "buy" rating and issued a $7.00 target price on shares of BioAtla in a research report on Wednesday.May 15, 2024 | msn.comBioAtla, Inc. (NASDAQ:BCAB) Q1 2024 Earnings Call TranscriptMay 15, 2024 | finance.yahoo.comBioAtla Inc (BCAB) (Q1 2024) Earnings Call Transcript Highlights: Strategic Adjustments and ...May 14, 2024 | investorplace.comBCAB Stock Earnings: BioAtla Beats EPS for Q1 2024May 14, 2024 | globenewswire.comBioAtla Reports First Quarter 2024 Financial Results and Highlights Recent ProgressMay 8, 2024 | globenewswire.comBioAtla to Participate in the Citizens JMP Life Sciences ConferenceMay 7, 2024 | finance.yahoo.comBioAtla to Announce First Quarter 2024 Financial Results and Provide Business Highlights on May 14, 2024May 6, 2024 | markets.businessinsider.comBioAtla Says FDA Clears IND Application For BA3361 For The Treatment Of Multiple TumorsMay 6, 2024 | globenewswire.comBioAtla Announces FDA Clearance of Investigational New Drug Application for BA3361, a CAB-Nectin-4 Antibody Drug Conjugate for the Treatment of Multiple TumorsMay 3, 2024 | nasdaq.comBioAtla, Inc. Common Stock (BCAB)May 2, 2024 | seekingalpha.comBioAtla: A Buried ADC Concern Gets Some New Life In 2024April 30, 2024 | finance.yahoo.comBioAtla, Inc. (BCAB)April 24, 2024 | globenewswire.comBioAtla Announces Upcoming Poster Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual MeetingApril 11, 2024 | markets.businessinsider.comBuy Rating Affirmed for BioAtla on Strong Clinical Pipeline and Financial StabilityApril 5, 2024 | seekingalpha.comGRIN, WOOF and MRNS are among after hour moversMarch 29, 2024 | marketbeat.comBioAtla, Inc. Expected to Earn FY2028 Earnings of ($0.09) Per Share (NASDAQ:BCAB)BioAtla, Inc. (NASDAQ:BCAB - Free Report) - Stock analysts at HC Wainwright issued their FY2028 earnings per share (EPS) estimates for shares of BioAtla in a report released on Wednesday, March 27th. HC Wainwright analyst A. He expects that the company will post earnings per share of ($0.09) forMarch 28, 2024 | marketbeat.comBioAtla's (BCAB) "Market Outperform" Rating Reiterated at JMP SecuritiesJMP Securities reissued a "market outperform" rating and set a $12.00 price objective on shares of BioAtla in a research note on Thursday.March 27, 2024 | markets.businessinsider.comOptimistic Outlook for BioAtla’s Pipeline Progression and Potential PartnershipsMarch 27, 2024 | finance.yahoo.comBioAtla, Inc. (NASDAQ:BCAB) Q4 2023 Earnings Call TranscriptMarch 26, 2024 | benzinga.comBioAtla: Q4 Earnings InsightsMarch 26, 2024 | finance.yahoo.comBioAtla Inc (BCAB) Posts Q4 and Full Year 2023 Financial ResultsMarch 26, 2024 | globenewswire.comBioAtla Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent ProgressMarch 25, 2024 | benzinga.comPreview: BioAtla's EarningsMarch 20, 2024 | marketbeat.comBioAtla (BCAB) Set to Announce Earnings on TuesdayBioAtla (NASDAQ:BCAB) will be releasing earnings after the market closes on Tuesday, March 26, Zacks reports.March 19, 2024 | globenewswire.comBioAtla to Announce Fourth Quarter and Full-Year 2023 Financial Results and Provide Business Highlights on March 26, 2024March 7, 2024 | globenewswire.comBioAtla Announces Poster Presentations at the 2024 American Association for Cancer Research (AACR) Annual MeetingMarch 7, 2024 | marketbeat.comDeutsche Bank AG Sells 413,268 Shares of BioAtla, Inc. (NASDAQ:BCAB)Deutsche Bank AG cut its holdings in BioAtla, Inc. (NASDAQ:BCAB - Free Report) by 59.7% during the third quarter, according to its most recent Form 13F filing with the SEC. The firm owned 279,122 shares of the company's stock after selling 413,268 shares during the period. Deutsche Bank AG owned 0.March 6, 2024 | edition.cnn.comBioAtla, Inc.February 13, 2024 | marketbeat.comMassachusetts Financial Services Co. MA Sells 227,686 Shares of BioAtla, Inc. (NASDAQ:BCAB)Massachusetts Financial Services Co. MA decreased its stake in BioAtla, Inc. (NASDAQ:BCAB - Free Report) by 30.1% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 528,667 shares of theJanuary 24, 2024 | markets.businessinsider.comStrong Buy for BioAtla: Promising ADC Developments and Strategic Oncology PipelineJanuary 10, 2024 | markets.businessinsider.comBuy Rating for BioAtla Amid Robust Pipeline and Encouraging Clinical TrialsJanuary 1, 2024 | markets.businessinsider.comBTIG Keeps Their Buy Rating on BioAtla (BCAB)December 23, 2023 | finance.yahoo.comCo-Founder of BioAtla Jay Short Buys 2.3% More SharesDecember 21, 2023 | msn.comBioAtla CEO purchases 50K common sharesDecember 20, 2023 | finance.yahoo.comBioAtla to Participate in the 42nd Annual J.P. Morgan Healthcare ConferenceDecember 18, 2023 | markets.businessinsider.comStrong Buy Rating for BioAtla Reflects Potential of BA3071 and Promising Clinical ResultsDecember 16, 2023 | marketbeat.comBioAtla, Inc. (NASDAQ:BCAB) Short Interest UpdateBioAtla, Inc. (NASDAQ:BCAB - Get Free Report) was the recipient of a significant growth in short interest during the month of November. As of November 30th, there was short interest totalling 4,450,000 shares, a growth of 8.0% from the November 15th total of 4,120,000 shares. Based on an average trading volume of 408,600 shares, the short-interest ratio is currently 10.9 days.December 15, 2023 | finance.yahoo.comAfter losing 78% in the past year, BioAtla, Inc. (NASDAQ:BCAB) institutional owners must be relieved by the recent gainDecember 14, 2023 | markets.businessinsider.comBuy Rating Affirmed for BioAtla Amid Promising BA3071 Clinical Data and Favorable Safety ProfileDecember 13, 2023 | finance.yahoo.comBioAtla Hosting Virtual R&D Day to Highlight BA3071 CAB-CTLA-4 Phase 1 Data in Multiple Solid Tumor TypesDecember 12, 2023 | morningstar.comBioAtla Inc Ordinary SharesDecember 6, 2023 | finance.yahoo.comBioAtla to Host Virtual R&D Day to Review BA3071 CAB-CTLA-4 Phase 1 Data in Multiple Solid Tumor Types on Wednesday, December 13, 2023 Get BioAtla News Delivered to You Automatically Sign up to receive the latest news and ratings for BCAB and its competitors with MarketBeat's FREE daily newsletter. Email Address Claim Your Complimentary Bitcoin Reward (Ad)Many have already secured their free Bitcoin reward offered by our esteemed guest. How about you? In an effort to spread the word about our upcoming workshop, he's generously offering $10 in Bitcoin (BTC) to participants. Absolutely no strings attached. Secure Your Spot Now BCAB Media Mentions By Week BCAB Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. BCAB News Sentiment▼0.740.76▲Average Medical News Sentiment BCAB News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. BCAB Articles This Week▼21▲BCAB Articles Average Week Get BioAtla News Delivered to You Automatically Sign up to receive the latest news and ratings for BCAB and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: REPL News SOPH News SLDB News PSTX News AGEN News BDTX News CRBU News ADAP News IPSC News MGX News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:BCAB) was last updated on 6/2/2024 by MarketBeat.com Staff From Our PartnersBiden Nomination CANCELED?The Freeport SocietyTrump’s Gift Could Unleash $51 Billion in New WealthWealthpin ProBiden replacement revealed?Paradigm PressBuy this small stock before coming AI Tidal WaveChaikin AnalyticsWarren Buffett, Jeff Bezos, Michael Bloomberg, & 48 Members of Congress Are Buying ONE Sector…InvestorPlaceNvidia has Apple and Microsoft within striking rangeWeiss RatingsDon’t buy a single NVIDIA share before you see this...Behind the MarketsExposed: 10 CENT Crypto to Explode May 20th?True Market Insiders Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioAtla, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
